About Alpha-2C adrenergic receptor
Alpha-2C adrenergic receptor (ADRA2C) is a protein
from Homo sapiens identified by UniProt accession
P18825, 462 residues long.
MolForge cross-references it against 0 known binders and
343 disease associations.
Target properties
| Protein name | Alpha-2C adrenergic receptor |
| UniProt accession | P18825 |
| Gene | ADRA2C |
| Organism | Homo sapiens |
| Length | 462 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (343)
Diseases linked to this target (Open Targets).
- pain · score 0.61
- unipolar depression · score 0.60
- attention deficit hyperactivity disorder · score 0.60
- Nasal congestion · score 0.60
- hypotension · score 0.60
- seasonal allergic rhinitis · score 0.60
- hypertension · score 0.60
- delirium · score 0.60
- asthma · score 0.60
- glaucoma · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P18825-F1 | alphafold | PREDICTED | 72.83 | — |
Amino-acid sequence (462 residues)
MASPALAAAL AVAAAAGPNA SGAGERGSGG VANASGASWG PPRGQYSAGA VAGLAAVVGF LIVFTVVGNV LVVIAVLTSR ALRAPQNLFL VSLASADILV ATLVMPFSLA NELMAYWYFG QVWCGVYLAL DVLFCTSSIV HLCAISLDRY WSVTQAVEYN LKRTPRRVKA TIVAVWLISA VISFPPLVSL YRQPDGAAYP QCGLNDETWY ILSSCIGSFF APCLIMGLVY ARIYRVAKLR TRTLSEKRAP VGPDGASPTT ENGLGAAAGA GENGHCAPPP ADVEPDESSA AAERRRRRGA LRRGGRRRAG AEGGAGGADG QGAGPGAAES GALTASRSPG PGGRLSRASS RSVEFFLSRR RRARSSVCRR KVAQAREKRF TFVLAVVMGV FVLCWFPFFF SYSLYGICRE ACQVPGPLFK FFFWIGYCNS SLNPVIYTVF NQDFRRSFKH ILFRRRRRGF RQ
Explore Alpha-2C adrenergic receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets